Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
Disease control
Terminated
This phase 2 trial compares a new combination of camrelizumab (an immunotherapy) plus apatinib (a targeted therapy) against the standard chemotherapy plus bevacizumab as a first treatment for women with stage IVB, recurrent, or persistent cervical cancer. The study aims to see if…
Phase: PHASE2 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC